期刊
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS
卷 1182, 期 -, 页码 69-79出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.05069.x
关键词
Interferon-gamma; Actimmune; HuZaf
资金
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
Interferon gamma (IFN-gamma), a pleotropic cytokine, has been shown to be important to the function of virtually all immune cells and both innate and adaptive immune responses. In 1986, early clinical trials of this cytokine began to evaluate its therapeutic potential. The initial studies focused on the tolerability and pharmacology of IFN-gamma and systematically determined its antitumor and anti-infection activities. In the 20-plus years since those first trials, IFN-gamma has been used in a wide variety of clinical indications, which are reviewed in this article.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据